Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...
China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...
France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...
Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...